Compare Heron Therapeutics Inc (HRTX) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Williams-Sonoma, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $68.01M), while Williams-Sonoma, Inc. trades at $239 (market cap $28.15B). The key difference: Williams-Sonoma, Inc. is far larger — about 413.9× Heron Therapeutics Inc's market cap, and Williams-Sonoma, Inc. pays a 1.27% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Williams-Sonoma, Inc. for 59 Days on average.
| HRTX | WSM | |
|---|---|---|
Market Cap | $68.01M | $28.15B |
Volume | 1,891,941 | 1,351,262 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.49 | $251.81 |
52-Week Low | $0.27 | $168.64 |
Typical Hold Time | 35 Days | 59 Days |
Enterprise Value | $174.75M | $28.65B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Williams-Sonoma (WSM) trades at $240.46, down 0.74% on the day, with a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.10 surpassing expectations. Revenue for 2025 was $7.71 billion, with a robust net income margin of 14.73% and high return on equity of 54.96%. Recent news highlights market share gains and AI integration driving growth.
The outlook remains positive with a consensus price target of $246.31, suggesting moderate upside. Key opportunities include sustained margin strength and digital initiatives, while risks involve housing market sensitivity and competitive pressures. Institutional sentiment is mixed with 32% buy ratings, but recent insider selling by the CFO warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
